Medline to Exit Bed Market as Field Action Costs Are Estimated at Up to $220 Million
Medline initiated a voluntary field action on October 14, 2026, to remove, discontinue, and exit the market for all Medline Brand beds, along with related pendants, accessories, parts, and order packages. The company estimates associated costs of up to $220 million, to be incurred in 2026 and 2027 and excluded from Adjusted EBITDA, which is a clear charge for shareholders, though it does not currently expect a material impact on fiscal 2026 financial results or its full-year 2026 guidance.
Key points
- Voluntary field action initiated October 14, 2026, covering all Medline Brand beds, including homecare, bariatric, and long-term care beds.
- Affected products had net sales of approximately $60 million for the twelve months ended June 27, 2026.
- Estimated associated costs of up to $220 million, expected in 2026 and 2027, to be excluded from Adjusted EBITDA; actual customer credits may differ materially.
- Company does not currently expect a material impact on fiscal 2026 results, including full-year 2026 guidance provided August 5, 2026.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.